Toll样受体基因多态与肿瘤易感性的研究进展

doi:10.3969/j.issn.1004-616x.2014.03.017

摘要/Abstract

摘要：

肿瘤的发生和发展是一个复杂的多因素多机制的过程，研究其易感基因的多态性对于阐明疾病易感性机制、设计个体化治疗方案和环境危险因素的评价与预警等均具有重要意义。Toll样受体既可以活化和促进肿瘤细胞的增殖和生长，也可以通过募集炎性细胞或激活免疫反应来抑制和杀灭肿瘤细胞，可调控肿瘤的发生、发展和周围细胞的免疫反应。Toll样受体基因的多态性使其编码的蛋白或传导的信号发生改变，从而使人群出现对某些肿瘤不同的遗传易感性，其基因特定位点的变异可影响肿瘤的发生和发展。本文就近年来有关Toll样受体基因多态性与肿瘤易感性的相关研究作一概述。

关键词: Toll样受体, 基因多态性, 遗传易感性, 肿瘤

黄标通，周新民，龙建平. Toll样受体基因多态与肿瘤易感性的研究进展[J]. 癌变·畸变·突变, doi: 10.3969/j.issn.1004-616x.2014.03.017.

参考文献

[1] Janssens S，Beyaert R. Role of Toll-like receptors in pathogen recognition[J]. Clin Microbiol Rev，2003，16(4)：637-646.

[2] Akira S，Uematsu S，Takeuchi O. Pathogen recognition and innate immunity[J]. Cell，2006，124(4)：783-801.

[3] Akira S，Takeda K，Kaisho T. Toll-like receptors：critical proteins linking innate and acquired immunity[J]. Nature Immunol，2001，(2)8：675-680.

[4] Huang B，Zhao J，Li H，et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance[J]. Cancer Res，2005，65(12)：5009-5014.

[5] Cherfils-Vicini J，Platonova S，Gillard M，et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance[J]. J Clin Invest，2010， 120(4)：1285-1297.

[6] Schmausser B，Andrulis M，Endrich S，et al. Toll-like receptors TLR4，TLR5 and TLR9 on gastric carcinoma cells：An implication for interaction with Helicobacter pylori[J]. Int J Med Microbiol，2005，295(3)：179-185.

[7] Szczepanski M，Stelmachowska M，Stryczynski L，et al. Assessment of expression of toll-like receptors 2，3 and 4 in laryngeal carcinoma[J]. Eur Arch Otorhinolaryngol，2007， 264(5)：525-530.

[8] Cai Z，Sanchez A，Shi Z，et al. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth[J]. Cancer Res，2011，71(7)： 2466-2475.

[9] Kim WY， Lee JW，Choi JJ，et al. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia[J]. Int J Gynecol Cancer，2008，18：300-305.

[10] Zhou M，McFarland-Mancini MM，Funk HM，et al. Toll-like receptor expression in normal ovary and ovarian tumors[J]. Cancer Immunol Immunother，2009，58(9)：1375-1385.

[11] Garay，RP，Viens R，Bauer J，et al. Cancer relapse under chemotherapy：why TLR2/4 receptor agonist can help[J]. Eur J Pharmacol，2007，563(1)：1-17.

[12] Krieg AM. Development of TLR9 agonists for cancer therapy[J]. J Clin Invest，2007，117(5)：1184-1194.

[13] Fukata M，Hernandez Y，Conduah D，et al. Innate immune signaling by Toll-like receptor-4 (TLR4)shapes the inflammatory microenvironment in colitis-associated tumors[J]. Inflamm Bowel Dis，2009，15(7)：997-1006.

[14] 黄华. Toll样受体4基因(TLR4)多态性与胃癌易感性的关联研究[D]. 南京：南京医科大学，2010.

[15] 张丽. 中国汉族人群单核苷酸多态性与幽门螺杆菌相关性胃癌的关系研究[D]. 重庆：重庆医科大学，2011.

[16] Achyut BR，Ghoshal UC，Moorchung N，et al. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions[J]. Hum Immunol，2007，68(11)：901-907.

[17] Santini D，Angeletti S，Ruzzo A，et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes[J]. Clin Exp Immunol，2008， 154(3)：360-364.

[18] Tahara T，Arisawa T，Wang F，et al. Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Japanese people to gastric cancer[J]. Cancer Sci，2007， 98(11)：1790-1794.

[19] Hold GL，Rabkin CS，Gammon MD，et al. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations[J]. Eur J Cancer Prev， 2009 ，18(2)：117-119.

[20] 陈丽珊，郭秋莎，夏冰. CD14及TLR4基因多态性与大肠癌的相关性研究[C]. 中华医学会第七次全国消化病学术会议论文汇编(下册)：中华医学会消化病学分会，2007：1.

[21] 蒋益，闵小彦，高劲松. Toll样受体4基因-299位点A/G多态性与溃疡性结肠炎及大肠腺癌的关系[J]. 长沙医学院学报，2007，2(1)：13-17.

[22] Castro FA，F?rsti A，Buch S，et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer[J]. Eur J Cancer，2011，47(8)：1203-1210.

[23] 陈小军. IL12A、IL12B和TLR9基因多态性与宫颈癌易感性的关联研究[D]. 南京：南京医科大学，2009.

[24] Pandey S，Mittal RD，Srivastava M，et al. Impact of Toll-like receptors [TLR] 2 (-196 to -174 del) and TLR 4 (Asp299Gly， Thr399Ile) in cervical cancer susceptibility in North Indian women [J]. Gynecol Oncol，2009，114(3)：501-505.

[25] Pandey S，Mittal B，Srivastava M，et al. Evaluation of Toll-like receptors 3(c.1377C/T) and 9(G2848A) gene polymorphisms in cervical cancer susceptibility[J]. Mol Biol Rep，2011， 38(7)：4715-4721.

[26] Priyadarshini A，Chakraborti A，Mandal AK，et al. Asp299Gly and Thr399Ile polymorphism of TLR-4 gene in patients with prostate cancer from North India[J]. Indian J Urol，2013，29(1)：37-41.

[27] Mandal RK，George GP，Mittal RD. Association of Toll-like receptor (TLR) 2，3 and 9 genes polymorphism with prostate cancer risk in North Indian population[J]. Mol Biol Rep， 2012，39(7)：7263-7269.

[28] Stark JR，Wiklund F，Gr?nberg H，et al. Toll-like receptor signaling pathway variants and prostate cancer mortality[J]. Cancer Epidemiol Biomarkers Prev，2009，18(6)：1859-1863.

[29] Srivastava K，Srivastava A，Kumar A，et al. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer[J]. Liver Int，2010，30(7)：1067-1072.

[30] 范蕾. 研究TLR3及其介导通路在乳腺癌发生发展中的地位[D]. 上海：复旦大学， 2010.

[31] 邹立君，张合喜，王友洁，等. TLR9基因多态性与肺癌易感性的关系[J]. 环境与职业医学，2006，1：8-10.

[32] Gast A，Bermejo JL，Claus R，et al. Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival[J]. PLoS One，2011，6(9)：24370.

[33] Kim SK，Park HJ，Hong IK，et al. A missense polymorphism (rs11466653，Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population[J]. Endocrine，2013，43(1)：161-169.